Awareness and Prescribing Patterns of Acute and Preventive Migraine Medications Among General Practitioners: The Kawasaki Medical Association Study.

In Japan, new migraine treatments have recently become available. These include anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and lasmiditan. Despite these advancements, many doctors still do not frequently prescribe migraine medications. A study surveyed 1,274 physicians in Kawasaki to understand their awareness and prescribing habits. The survey ran from December 2024 to February 2025 and collected responses via fax and web. Out of the surveyed physicians, only 288 responded, resulting in a 22.6% response rate. Most respondents were general internists, with neurologists and neurosurgeons being fewer. For treating acute migraines, 65.9% of doctors mainly used acetaminophen or nonsteroidal anti-inflammatory drugs. While 87.8% of physicians knew about triptans, only 64.1% actually prescribed them. This indicates a gap between awareness and actual prescribing practices among doctors treating migraines in Kawasaki. Clinical relevance: This study highlights the need for improved education on migraine treatments among physicians.